Eli Lilly and Company revealed today that it is to acquire the clinical-stage biotechnology company Adverum Biotechnologies, Inc., which is the leader in the development of intravitreal gene therapy to restore vision in patients with advanced...
Novartis announced on Sunday that it will acquire U.S.-based Avidity Biosciences for about $12 billion in cash in one of its largest deals to strengthen its pipeline of treatments for rare muscle disorders. Under the terms of the deal, Avidity...
Syngene International Ltd., a global leader in contract research, development, and manufacturing (CRDMO) services, has unveiled plans to set up a cutting-edge GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru
According to Novartis' announcement, APPLAUSE-IgAN randomized Phase III trial results have provided positive final results showing that Fabhalta (iptacopan) was demonstrated to significantly slow decline in kidney function in adults with IgA...
 (1).jpg "Ipsen to Acquire ImCheck Therapeutics to Boost Cancer Pipeline")
Ipsen agreed to a definitive share purchase agreement to acquire ImCheck Therapeutics, a French privately-held biotechnology company that develops next-generation immuno-oncology therapies. Through this acquisition, Ipsen is focusing on the
.jpg "Experts Seek National Pharma Quality Audit Framework")
According to B Thirunavukkarasu, president of the Bangalore District Chemists and Druggists Association (BDCDA), India requires a national Pharma Quality Certification & Audit (PQCA) system under the Quality Council of India (QCI) to strengthen drug
GSK plc revealed that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a green signal to the approval of a new prefilled syringe presentation for Shingrix
Takeda Pharmaceutical Company and Innovent Biologics have orchestrated a global strategic alliance worth as much as $11.4 billion to expedite the creation of cutting-edge oncology drugs for solid tumors.
.png "AstraZeneca's Imfinzi Shows Major Gains in Gastric Cancer")
AstraZeneca's Imfinzi (durvalumab) has demonstrated a significant increase in survival for early-stage gastric (GC) and gastroesophageal junction cancers (GEJC), according to new data from the European Society for Medical Oncology (ESMO) 2025...
.png "Merck's Pimicotinib Shows Durable Gains in TGCT Phase 3 Study")
Merck KGaA, a premier science and technology company, today revealed up to-date Phase 3 data from the global MANEUVER trial of pimicotinib, an investigational CSF-1R antagonist developed in collaboration with Abbisko Therapeutics for the treatment...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")